PHQ-9
Articles tagged with “PHQ-9”
What Side Effect Data Tells Us About Ketamine Dosing
New analysis of NMDA receptor antagonist side effects in treatment-resistant depression underscores why dose optimization and early monitoring matter.
Ketamine Side Effects & When to Switch: New Clinical Guidance
New clinical guidance urges tracking PHQ-9 scores, monitoring side effects closely, and switching NMDA treatments sooner to reach remission faster.
NMDA Antagonist Side Effects: What the Data Now Shows
Psychiatric Times reviews side effect profiles and dropout rates for NMDA antagonists like ketamine. Here's what it means for low-dose ketamine patients.
Tracking Treatment Response to Ketamine: PHQ-9, MADRS, and Clinical Scales
A clinician's guide to systematic outcome measurement in ketamine therapy, covering validated rating scales, assessment frequency, response and remission thresholds, and data-driven decision-making for dosing adjustments.
Measuring Ketamine Treatment Outcomes: Validated Assessment Tools
How is ketamine response actually measured? A review of validated depression scales, suicidality tools, functional assessments, and biomarkers used in trials.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.